NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 25 filers reported holding NEUBASE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $43,285 | +98275.0% | 233,973 | 0.0% | 0.00% | – |
| Q4 2022 | $44 | -100.0% | 233,973 | -0.3% | 0.00% | – |
| Q3 2022 | $92,000 | -62.6% | 234,571 | 0.0% | 0.00% | – |
| Q2 2022 | $246,000 | -46.3% | 234,571 | -3.9% | 0.00% | – |
| Q1 2022 | $458,000 | -33.1% | 243,984 | 0.0% | 0.00% | – |
| Q4 2021 | $685,000 | -20.8% | 243,984 | +1.7% | 0.00% | – |
| Q3 2021 | $865,000 | -22.8% | 239,819 | +2.5% | 0.00% | – |
| Q2 2021 | $1,120,000 | -52.0% | 233,856 | -25.9% | 0.00% | – |
| Q1 2021 | $2,331,000 | +31.4% | 315,525 | +24.3% | 0.00% | – |
| Q4 2020 | $1,774,000 | -2.2% | 253,930 | +6.2% | 0.00% | – |
| Q3 2020 | $1,814,000 | +35.6% | 239,117 | +56.8% | 0.00% | – |
| Q2 2020 | $1,338,000 | +1063.5% | 152,486 | +840.9% | 0.00% | – |
| Q1 2020 | $115,000 | -50.4% | 16,206 | -50.0% | 0.00% | – |
| Q4 2019 | $232,000 | +193.7% | 32,412 | +103.1% | 0.00% | – |
| Q3 2019 | $79,000 | – | 15,960 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 906,445 | $3,272,000 | 1.04% |
| Greenlight Capital | 2,727,027 | $9,844,000 | 0.66% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 407,500 | $1,471,000 | 0.54% |
| CM Management, LLC | 75,000 | $271,000 | 0.20% |
| Stonepine Capital Management, LLC | 109,742 | $396,000 | 0.18% |
| GSA CAPITAL PARTNERS LLP | 351,178 | $1,268,000 | 0.13% |
| PERKINS CAPITAL MANAGEMENT INC | 21,000 | $76,000 | 0.05% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $1,123,000 | 0.03% |
| Polar Asset Management Partners Inc. | 634,618 | $2,291,000 | 0.02% |
| Point72 Asset Management, L.P. | 1,250,000 | $4,513,000 | 0.02% |